Let’s make that $1B-plus: Abing­worth gath­ers more cash, this time for its late-stage pok­er game. And we learned that even a biotech nu­clear win­ter has its ad­van­tages

Talk­ing with Kurt von Em­ster is al­ways in­ter­est­ing. The joint man­ag­ing part­ner has been track­ing all the fi­nan­cial and de­vel­op­ment trends that in­flu­ence his busi­ness at the glob­al play­er Abing­worth for years. He’s frank about the lessons — with­out di­vulging any se­crets, of course — and you can learn things from him about ther­a­peu­tic pro­grams, defin­ing true suc­cess and over­all risk in deal­mak­ing, that can oth­er­wise be hard to suss out.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE